Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
In this study, researchers are assessing the safety and effectiveness of using the drug ruxolitinib in patients with T-cell lymphoma or natural killer (NK)-cell lymphoma that has come back or continued to grow despite prior treatment. Ruxolitinib is already approved for treating a bone marrow disease called myelofibrosis. It works by inhibiting a protein called JAK, which works with another protein called STAT to promote the growth of many T-cell and NK-cell lymphomas. By blocking JAK, ruxolitinib may cause lymphomas to shrink.
Women with a mutation in the BRCA1 or BRCA2 genes are at increased risk for hereditary breast and ovarian cancer. However, the cancer risk estimates for these gene mutations are currently wide-ranging and non-specific. A new form of genetic testing, called "genetic risk modifier testing," may give women with BRCA1/2 gene mutations more specific estimates of their risk of developing breast cancer.
Isolated limb infusion (ILI) is a way to give anticancer drugs directly into an arm or leg to treat a sarcoma. However, despite this treatment, sometimes the cancer still spreads to other parts of the body. In this study, researchers want to see if adding the immunotherapy drug pembrolizumab to ILI treatment with the chemotherapy drugs melphalan and dactinomycin can help prevent the spread of cancer and increase the effectiveness of the ILI treatment in people with advanced sarcoma.
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal cancer and solid tumors including endometrial cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced MMR solid tumors or in people with early stage dMMR endometrial cancer and a strong desire for fertility preservation. Doctors will then evaluate patients' response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery.
The standard treatment for poor-risk and intermediate-risk germ cell tumors (GCTs), such as testicular cancer, is chemotherapy with the drugs bleomycin, etoposide, and cisplatin (abbreviated BEP) given every three weeks. In this study, researchers want to see if giving BEP chemotherapy every two weeks is more effective for controlling tumor growth than the standard regimen in patients with metastatic intermediate-risk and poor-risk GCTs.
The purpose of this study is to assess the safety and effectiveness of combining three drugs to treat people with an IDH-mutant glioma that came back after chemotherapy or surgery. The three medications are pembrolizumab, olaparib, and temozolomide.
Plasmablastic lymphoma is a type of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study is to determine if adding daratumumab to a standard chemotherapy regimen (DA-EPOCH) is a safe way to increase the effectiveness of treatment in people with plasmablastic lymphoma.
The purpose of this study is to assess the safety and effectiveness of partial breast radiation therapy given over a three-day period (three weekdays in a row) in women with ductal carcinoma in situ (DCIS) or early-stage invasive breast cancer after lumpectomy. Women who are not in a research study usually receive radiation therapy to the whole breast over three weeks or receive partial breast irradiation over a five- to ten-day period.
This study aims to obtain a better understanding of the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. Together these diseases are referred to as "lymphoproliferative disorders."
